(Il Sole 24 Ore Radiocor) - Milano, 6 mag - Dutch health technology company Philips said that in the first quarter sales fell a nominal 5% but rose a comparable 4% to 3.905 billion euros, while order intake rose a like for like 6%, accelerating from the 2% rise seen in the same year-ago period.

Diagnosis & Treatment saw comparable sales increase by 2%, Connected Care by 3%, and Personal Health by 9%.

Income from operations increased to 241 million euros from 154 millio euros and was 6% of sales from 4% a year ago. The rise mainly reflected operational improvements, and lower charges in restructuring, acquisition-related and other items, including a release of an acquisition-related provision, and partly offset by higher tariffs.

Adjusted EBITA was 353 million euros from 354 million a year ago and the margin improved to 9% from 8.6% thanks to sales growth, gross margin from innovation, and productivity measures, and partly offset by higher tariffs and cost inflation.

Diagnosis & Treatment saw an adjusted EBITA margin of 9.8%, up 30 basis points, mainly driven by higher sales andproductivity, partly offset by higher tariffs and cost inflation. In Connected Care, the margin fell 60 basis points to 2.9% due to higher tariffs and cost inflation. In Personal Health it rose 60 basis points to 15.8% driven by higher sales and productivity, and partly offset by higher tariffs, advertising and promotions spend, and cost inflation.

Restructuring, acquisition-related and other items amounted to charges of 61 million euros, compared with 143 million euros a year ago. The first quarter of 2026 included 61 million euros in restructuring charges and 34 million euros of Respironics-related charges, and is partly offset by a 42 million euro gain from the release of an acquisition-related provision.

Net income increased to 146 million euros from 72 million euros a year ago, mainly driven by income from operations and partly offset by higher taxes.

For the full year, Philips reiterated its outlook of comparable sales growth of 3-4.5% and an adjusted EBITA amrgin of 12.5-13%, with free cash flow of 1.3-1.5 billion euros.

The outlook includes currently known information, including tariffs, within an uncertain macro environment. It excludes any potential International Emergency Economic Powers Act (IEEPA) tariff refunds. It excludes ongoing Philips Respironics-related proceedings, including the investigation.

by the US Department of Justice.

(RADIOCOR) 06-05-26 09:10:35 (0221) 5 NNNN